TrialClinical immunology (Orlando, Fla.)2009

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Kevan C Herold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.